Market Signal Briefing

, /PRNewswire/ -- The International Stock Exchange Group Limited (TISE), a wholly-owned subsidiary of Miami International Holdings, Inc. (MIAX) (NYSE: MIAX), today announced the signing of a Memorandum of Understanding (MoU) with Boursa Kuwait to explore opportunities for collaboration in facilitating specialized listings and expanding Middle Eastern investment channels.

Boursa Kuwait is a leading regional exchange classified as an emerging market in major global indices. 

TISE is a regulated exchange offering a growing range of financial products. Headquartered in Guernsey, it maintains a presence and has members based in key international financial centers including Dublin, Jersey and London.

"We are pleased to sign this MoU with Boursa Kuwait as we share a common vision of developing a more interconnected and sustainable financial environment," said Cees Vermaas, Chief Executive Officer of TISE. "Through knowledge sharing and the exploration of opportunities for collaboration in areas such as specialized listings and innovative products, we aim to create new investment opportunities. We look forward to working alongside one of the most prominent exchanges in the Middle East to promote market integration and connect global investors with the promising opportunities in Kuwait and the wider region." 

The MoU aims to enhance technical and knowledge-based cooperation between the two parties. It also seeks to explore opportunities for financial market development through the exchange of expertise, collaboration in the innovation of new financial products and support for sustainable finance initiatives. It is part of Boursa Kuwait's ongoing efforts to strengthen its international presence and reinforce the Kuwaiti capital market's reputation as a trusted destination for regional and international investors.

"The signing of this MoU reaffirms Boursa Kuwait's commitment to fostering international cooperation and exchanging expertise with global financial institutions, further enhancing the Kuwaiti capital market's position as an attractive investment destination in the region," said Mohammad Saud Al-Osaimi, Chief Executive Officer of Boursa Kuwait. "This partnership represents a significant step toward exploring opportunities for developing financial products, supporting sustainable finance initiatives, and sharing knowledge in areas such as financial technology and market infrastructure."

The signing of this MoU comes amid growing ties between Guernsey and the State of Kuwait. It follows a similar MoU signed in August 2025 between the Guernsey Financial Services Commission and the Capital Markets Authority of Kuwait, which underscored both parties' commitment to strengthening regulatory cooperation and exchanging expertise to advance regulatory frameworks and enhance supervisory efficiency and governance.

About TISE

TISE provides financial markets and securities services to companies globally. TISE's Qualified Investor Bond Market (QIBM) is a leading market in Europe for listing high yield bonds, structured finance products and securitization transactions. TISE lists a pool of investment funds, UK Real Estate Investment Trusts (REITs) and hosts a sustainable finance segment, TISE Sustainable. TISE is headquartered in Guernsey, Channel Islands. To learn more about TISE, visit www.tisegroup.com.

About MIAX

Miami International Holdings, Inc. (NYSE: MIAX) is a technology-driven leader in building and operating regulated financial markets across multiple asset classes and geographies. MIAX operates nine exchanges across options, futures, equities and international markets including MIAX® Options, MIAX Pearl®, MIAX Emerald®, MIAX Sapphire®, MIAX Pearl Equities™, MIAX Futures™, MIAXdx™, The Bermuda Stock Exchange (BSX) and The International Stock Exchange (TISE). MIAX also owns Dorman Trading, a full-service Futures Commission Merchant. To learn more about MIAX, please visit www.miaxglobal.com.

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

The press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities of Miami International Holdings, Inc. (together with its subsidiaries, the Company), and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer; solicitation or sale would be unlawful. This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

All third-party trademarks (including logos and icons) referenced by the Company remain the property of their respective owners. Unless specifically identified as such, the Company's use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between the owners of these trademarks and the Company. Any references by the Company to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Media Contact:
Mark Oliphant, Head of Marketing & Communications, TISE
+44 (0) 1481 753011
[email protected]

SOURCE The International Stock Exchange Group

December 23, 2025 04:00 ET

 | Source:

HSBC Continental Europe

PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) --

Deutsche Post AG

HSBC (contact: [email protected]) hereby gives notice that no stabilisation was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Issuer:Deutsche Post AGGuarantor (if any):naAggregate nominal amount:EUR 750,000,000                       /  EUR 600,000,000Description:3% due 25th November 2031     /  3.75% due 25th November 2037       Offer price:99.498                                         / 99.063Stabilising Manager:HSBC Continental Europe This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Key Takeaways Enhertu-Perjeta gets FDA nod as first-line option for unresectable or metastatic HER2-positive breast cancer.Phase III DESTINY-Breast09 showed PFS of 40.7 months vs 26.9 months, reducing progression risk by 44%.Following approval, Daiichi is entitled to receive a $150 million milestone under the Enhertu collaboration.
AstraZeneca PLC (AZN - Free Report) and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer. Enhertu (trastuzumab deruxtecan) is now approved in combination with Roche’s Perjeta (pertuzumab) as first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer in the United States. This approval is based on data from the phase III DESTINY-Breast09 study, followed by a priority review and Breakthrough Therapy designation by the FDA.

The regulatory application for Enhertu was reviewed under the FDA’s real-time oncology review (RTOR) program.

Enhertu is already approved for the second-line treatment of patients with HER2-positive breast cancer in more than 85 countries, including the United States. It is also approved in HER2-targeted indications for lung and gastric cancers.

Following the approval of Enhertu for first-line use in breast cancer, AstraZeneca is entitled to pay Daiichi Sankyo $150 million as a milestone payment.

Over the past year, AZN’s shares have surged 36.3% compared with the industry’s 12.1% rise.

Image Source: Zacks Investment Research

DESTINY-Breast09 Study Data Supports Enhertu’s Expanded UseIn the DESTINY-Breast09 study, the Enhertu-Perjeta combination demonstrated a statistically significant improvement in progression-free survival and reduced the risk by 44% compared with the current standard regimen — taxane chemotherapy combined with Roche’s cancer drugs Herceptin and Perjeta (“THP”) for patients with HER2-positive metastatic breast cancer. The median progression-free survival (PFS) was 40.7 months for patients treated with the Enhertu-Perjeta combo, compared with 26.9 months with THP.

AstraZeneca and Daiichi entered a global collaboration in March 2019 to jointly develop and commercialize Enhertu, followed by an expansion of the partnership in July 2020 to include Datroway (datopotamab deruxtecan). Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu and Datroway. Daiichi records sales of Enhertu in the United States.

AZN’s Zacks Rank & Stocks to ConsiderAZN currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , CorMedix (CRMD - Free Report) and Castle Biosciences (CSTL - Free Report) . ANIP, CRMD and CSTL currently sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have increased from $7.29 to $7.54. Over the same period, EPS estimates for 2026 have surged from $7.79 to $8.15. Shares of ANIP have surged 46% in the past year.

ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.

Over the past 60 days, estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87, while 2026 EPS estimates have risen from $2.49 to $2.88 over the same period. Shares of CRMD have surged 32.7% over the past year.

CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.

Over the past 60 days, the loss estimate for Castle Biosciences has narrowed from 65 cents to 34 cents in 2025. Over the same period, loss estimates for 2026 have improved from $2.10 to $1.06. CSTL stock has rallied 38.2% over the past year.

Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 66.11%

(We are reissuing this article to correct a mistake. The original article, issued on December 16, 2025, should no longer be relied upon.).

This REIT offers a really high dividend yield.

The S&P 500's dividend yield is currently around 1.2%. So, when a stock like Annaly Capital Management (NLY +2.47%) offers a yield more than 10 times above that level, it seems like something is off.

However, that's not the case with this real estate investment trust (REIT). It must legally pay out 90% of its taxable income in dividends to remain in compliance with IRS regulations.

Image source: Getty Images.

A monster yield from the real estate sector
Annaly Capital Management is a mortgage REIT. It invests in Agency mortgage-backed securities (mortgage pools guaranteed against credit losses by government agencies, such as Fannie Mae), non-agency residential mortgages, and mortgage servicing rights. These mortgage investments typically yield low-risk, fixed-rate returns in the low to mid-single digits. Through the use of leverage, Annaly can earn higher returns, currently in the double digits across all three strategies.

The mortgage REIT reported $0.73 per share of earnings available for distribution (EAD) in the third quarter, up from $0.66 per share in the year-ago period. That easily covered its $0.70 per share dividend payment. Its EAD was $0.73 per share in the second quarter and $0.72 per share in the prior two quarters. The improvement in EAD over the past year enabled Annaly Capital Management to hike its dividend payment earlier this year from its previous level of $0.65 per share.

As long as Annaly's EAD remains above the current dividend level, it will be able to maintain the payment rate. However, its EAD can fluctuate based on interest rates and market conditions. In 2022, Annaly's EAD was between $0.89 and $1.22 per share, which enabled it to pay a quarterly dividend of $0.88 per share.

Annaly has a legal requirement to pay out nearly all of its taxable net income in dividends, which is why it has such a high yield. However, that payout will fluctuate with its earnings, which is something investors need to consider before buying shares for income.

Matt DiLallo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Societe Generale share price has done well in the past few months and is slowly nearing its highest point on record. It jumped to a high of €67.85, its highest point since May 2007. It has soared by 680% from its lowest point in 2021, bringing its market capitalization to over €51 billion. 

Copy link to section

The Societe Generale stock price has been in a strong uptrend in the past few months, mirroring the performance of other European banks like Unicredit, Lloyds, and Barclays.

The stock did well as the company’s revenue and profitability growth gained steam, even as the European Central Bank (ECB) delivered its interest rate cuts during the two years.

For example, the most recent results showed that the company’s revenue jumped by 5.7% in the first nine months of the year to €20.5 billion.

The revenue increase coincided with its cost reduction process. Its costs dropped by 2.2%, much higher than what it had predicted. This decline was because of its asset disposals and layoffs.

Societe Generale’s net income stood at €4.6 billion in the first nine months of the year, up by 45% from the same period last year. All these numbers were much better than its guidance.

At the same time, the company continued returning cash to investors in the form of dividends and share buybacks. The company recently completed its €1 billion share buyback program and announced a new €872 million dividend.

Meanwhile, the stock has benefited from its simplification process as it exited key markets like Guinea and Mauritania. It also exited its private banking businesses in Switzerland and the UK. 

The company, like other major players in the markets, benefited from the trading boom because of Donald Trump’s volatility. Its Global Banking and Investor Solutions business made €2.5 billion in the third quarter, up by 1.6% from the same period last year. 

Societe Generale’s balance sheet also continued to improve, with its CET1 ratio rising to 13.7% from 13.3% in the same period last year.

Still, the main risk for the stock is whether it can replicate its performance in the coming year now that interest rates are coming down. The ECB has slashed interest rates to 2%, and some analysts predict that they may continue falling in 2026. 

Societe Generale stock price technical analysis 
Copy link to section

Société Générale stock price chart | Source: TradingView The weekly timeframe chart shows that the Societe Generale share price has been in a strong uptrend in the past few years as its revenue has jumped and its costs have dropped.

However, technical analysis suggests that the rally has become highly overbought and is at risk of a decline in the coming year.

The Relative Strength Index (RSI) has jumped to 76, up from last year’s low of 38. Similarly, the Stochastic Oscillator has continued rising and is now at the highest point in over a year.

Most importantly, the stock remains above the 50-week and 100-week Exponential Moving Averages, which are at €49 and €40.60. As such, there is a likelihood that the stock may go through a mean reversion.

Mean reversion is a situation where an asset moves back to its historical averages. As such, the stock may drop to the key psychological level at €50 and then resume the uptrend.

Most high-yielders typically have those yields for a reason. Some may still be worth buying.

HSBC Holdings said on Tuesday that Ann Godbehere, its senior independent director and board member who led the search for a new chair, would step down and retire at the bank's 2026 annual general meeting due to "personal and lifestyle reasons".

The CNN Money Fear and Greed index showed further improvement in the overall market sentiment, while the index moved to the “Greed” zone on Monday.

U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 200 points during the session. The S&P 500 also recorded gains for the third straight session.

The New York Stock Exchange will close at 1 p.m. ET on Wednesday and will be closed on Thursday for Christmas Day.

UniFirst Corp. (NYSE:UNF) received an acquisition proposal from Cintas Corp. (NASDAQ:CTAS) for $275 per share in cash.

On the economic data front, the Chicago Fed National Activity Index increased to -0.21 in September from a reading of -0.31 in August.

Most sectors on the S&P 500 closed on a positive note, with materials, industrials and financials stocks recording the biggest gains on Monday. However, consumer staples stocks bucked the overall market trend, closing the session lower.

The Dow Jones closed higher by around 228 points to 48,362.68 on Monday. The S&P 500 rose 0.64% to 6,878.49, while the Nasdaq Composite jumped 0.52% to 23,428.83 during Monday's session.

Investors are awaiting earnings results from Limoneira Co. (NASDAQ:LMNR) and Good Times Restaurants Inc. (NASDAQ:GTIM) today.

What Is CNN Business Fear & Greed Index?At a current reading of 56, the index moved to the “Greed” zone on Monday, versus a prior reading of 49.7.

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Read Next:

5 Stock Picks Last Week From Wall Street’s Most Accurate Analysts
Photo courtesy: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

HomeStock IdeasLong IdeasFinancials 

SummaryPayPal is upgraded from Buy to Strong Buy, despite recent underperformance and negative sentiment weighing on shares.PYPL trades at a 10x forward P/E, a steep discount to peers and the S&P 500, while delivering strong revenue and EPS growth.Robust free cash flow, high profitability, and aggressive share buybacks underscore management’s conviction and support valuation upside.Expansion in Buy Now, Pay Later (BNPL) and international markets positions PYPL for double-digit bottom-line growth and potential multiple re-rating. JasonDoiy/iStock Unreleased via Getty Images

We all can agree that PayPal (PYPL) stock price action has been frustrating. It's about 8% away from the 52-week low of $55.85, although the business fundamentals are improving. I guess the most challenging part is tied to

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PYPL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

About Jamie Ashcroft
Jamie Ashcroft, the News Editor for Proactive UK, has developed an impressive career in financial journalism, focusing on the small-cap sector for over fourteen years. Before joining the Proactive team, he was a stockbroker during the global financial crisis, a role that complemented his educational background - a first-class degree in Business and Economics and qualifications in software design and development.
As one of the early external hires at Proactive in 2009, Jamie contributed... Read more

About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.

Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.

We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.

The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.

Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.

Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.

Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.

Samsung Electronics said on Tuesday its unit Harman International has agreed to acquire German automotive supplier ZF Friedrichshafen's advanced driver assistance system (ADAS) business for 1.5 billion euros ($1.77 billion).

, /PRNewswire/ -- With reference to TORM plc's (NASDAQ: TRMD) (NASDAQ: TRMD A) company announcements dated 03 and 09 September 2025 regarding Hafnia Limited's ("Hafnia") potential acquisition of shares in TORM plc from Oaktree Capital Management, L.P. and its affiliates ("Oaktree"), TORM plc has been informed by Oaktree that this acquisition was completed on 22 December 2025.

Following completion of the acquisition, TORM plc understands that Oaktree holds 26,425,059 A shares, and Hafnia holds 14,156,061 A shares, out of a total of 101,332,707 A shares of USD 0.01 each.

Accordingly, following receipt of Oaktree's threshold notice, the board of directors will now undertake the processes required under article 5 of TORM plc's articles of association ("Articles") to determine whether the "threshold date" defined in the Articles (being the first time at which Oaktree and its affiliates have ceased to beneficially own at least one third of the issued shares, excluding any shares held in treasury) has occurred.

Once the threshold date has been determined, each of the office of the B director, the C share voting rights and the limitations on TORM plc's actions set out in Article 137 will cease to have effect on the threshold date in accordance with the Articles and the B and C share will be redeemed and cancelled.

Further announcements will be made as appropriate once these processes are concluded.

Contact
Mikael Bo Larsen, Head of Investor Relations
Tel.: +45 5143 8002

About TORM

TORM is one of the world's leading carriers of refined oil products. TORM operates a fleet of product tanker vessels with a strong commitment to safety. environmental responsibility and customer service. TORM was founded in 1889 and conducts business worldwide. TORM's shares are listed on Nasdaq in Copenhagen and on Nasdaq in New York (ticker: TRMD A and TRMD. ISIN: GB00BZ3CNK81). For further information, please visit www.torm.com.

Safe Harbor Statement as to the Future

Matters discussed in this release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. Words such as, but not limited to, "expects," "anticipates," "intends," "plans," "believes," "estimates," "targets," "projects," "forecasts," "potential," "continue," "possible," "likely," "may," "could," "should" and similar expressions or phrases may identify forward-looking statements.

The forward-looking statements in this release are based upon various assumptions, many of which are, in turn, based upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, the Company cannot guarantee that it will achieve or accomplish these expectations, beliefs, or projections.

Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, our future operating or financial results; changes in governmental rules and regulations or actions taken by regulatory authorities; inflationary pressure and central bank policies intended to combat overall inflation and rising interest rates and foreign exchange rates; general domestic and international political conditions or events, including "trade wars" and the war between Russia and Ukraine, the developments in the Middle East, including the war in Israel and the Gaza Strip, and the conflict regarding the Houthis' attacks in the Red Sea; international sanctions against Russian oil and oil products; changes in economic and competitive conditions affecting our business, including market fluctuations in charter rates and charterers' abilities to perform under existing time charters; changes in the supply and demand for vessels comparable to ours and the number of new buildings under construction; the highly cyclical nature of the industry that we operate in; the loss of a large customer or significant business relationship; changes in worldwide oil production and consumption and storage; risks associated with any future vessel construction; our expectations regarding the availability of vessel acquisitions and our ability to complete acquisition transactions planned; availability of skilled crew members other employees and the related labor costs; work stoppages or other labor disruptions by our employees or the employees of other companies in related industries;  effects of new products and new technology in our industry;  new environmental regulations and restrictions; the impact of an interruption in or failure of our information technology and communications systems, including the impact of cyber-attacks, upon our ability to operate; potential conflicts of interest involving members of our Board of Directors and Senior Management; the failure of counterparties to fully perform their contracts with us; changes in credit risk with respect to our counterparties on contracts; adequacy of insurance coverage; our ability to obtain indemnities from customers; changes in laws, treaties or regulations; our incorporation under the laws of England and Wales and the different rights to relief that may be available compared to other countries, including the United States; government requisition of our vessels during a period of war or emergency; the arrest of our vessels by maritime claimants; any further changes in U.S. trade policy that could trigger retaliatory actions by the affected countries; the impact of the U.S. presidential and congressional election results affecting the economy, future government laws and regulations and trade policy matters, such as the imposition of tariffs and other import restrictions; potential disruption of shipping routes due to accidents, climate-related incidents, adverse weather and natural disasters, environmental factors, political events, public health threats, acts by terrorists or acts of piracy on ocean-going vessels; damage to storage and receiving facilities; potential liability from future litigation and potential costs due to environmental damage and vessel collisions; and the length and number of off-hire periods and dependence on third-party managers.

In the light of these risks and uncertainties, undue reliance should not be placed on forward-looking statements contained in this release because they are statements about events that are not certain to occur as described or at all. These forward-looking statements are not guarantees of our future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements.

Except to the extent required by applicable law or regulation, the Company undertakes no obligation to release publicly any revisions or updates to these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Please see TORM's filings with the U.S. Securities and Exchange Commission for a more complete discussion of certain of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/torm-plc/r/major-shareholder-announcement,c4286010

The following files are available for download:

SOURCE Torm PLC

Taking a buy-and-hold approach to the chipmaker's stock could have made you a multimillionaire.

In December 2015, a loose group of researchers, engineers, and tech company leaders that included Sam Altman and Elon Musk came together in a San Francisco living room to articulate a vision for artificial intelligence (AI) that might actually benefit humanity one day.

A decade later, the fruits of that meeting are starting to surface in the real world.

One of the companies that has profited the most from that vision is "Magnificent Seven" powerhouse Nvidia (NVDA +1.49%). In the last decade, the hardware giant has evolved from a company best known for gaming GPUs into a trillion-dollar club member that's leading the AI infrastructure buildout.

Today's Change

(

1.49

%) $

2.70

Current Price

$

183.69

Considering that 10 years ago, Nvidia had a roughly $17 billion market cap, you'd probably expect a $10,000 investment made in it then to be worth a small fortune today.

But just how much it would be worth might make you do a double-take.

Image source: Nvidia.

A gain of over 22,000%
If you had invested $10,000 in Nvidia 10 years ago and held on through all the flat, rocky, and exhilarating years that followed, your current investment would be worth well over $2.2 million.

To put that into perspective, if you had invested the same amount in any of the other six Magnificent Seven stocks -- Apple, Amazon, Alphabet, Meta Platforms, Microsoft, and Tesla -- your returns would have been impressive, but nowhere close to what the chipmaker delivered.

NVDA Total Return Level data by YCharts.

Nvidia has earned its crown. For investors who believe AI spending will continue to climb, the stock remains a top pick to consider buying.

Steven Porrello has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ARES either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

ST HELIER, Jersey, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or "the Company") (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) announces that it received notification on December 22, 2025 from Mr Victor Gapare, an executive director of Caledonia and the settlor of a discretionary trust which ultimately owns the shares in Toziyana Resources Limited, the largest shareholder in the Company, (“Toziyana”) that Toziyana purchased 7,457 common shares in the Company on December 22, 2025 at a price of $26.83 per share (the “Purchase”).

Following the Purchase, Mr Victor Gapare now holds an interest, as the settlor of that trust, in common shares representing 12.66 per cent. of the Company’s issued share capital.

A copy of the notification is below.

Enquiries:

Caledonia Mining Corporation Plc
Mark Learmonth
Camilla Horsfall
Tel: +44 1534 679 800
Tel: +44 7817 841 793Cavendish Capital Markets Limited (Nomad and Broker)
Adrian Hadden
Tel: +44 207 397 1965Camarco, Financial PR (UK)
Gordon Poole
Elfie Kent
Tel: +44 20 3757 4980Curate Public Relations (Zimbabwe)
Debra Tatenda
Tel: +263 77802131IH Securities (Private) Limited (VFEX Sponsor - Zimbabwe)
Lloyd Mlotshwa
Tel: +263 (242) 745 119/33/39 NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 1Details of the person discharging managerial responsibilities/person closely associated

 a)NameVictor Gapare
 2Reason for the notification

 a)Position/statusExecutive Director
 b)Initial notification/ AmendmentInitial notification
 3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 a)NameCaledonia Mining Corporation Plc b)LEI21380093ZBI4BFM75Y51 4Detailsof the transaction(s): section to be repeated for (i) each typeof instrument;(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a) Description of the financial instrument, type of instrument Identification code

 Common shares of no par value JE00BF0XVB15

 b) Nature of the transaction Purchase of securities c)
 Price(s) and volume(s) Price(s) Volume(s) US$26.83  7,457  d) Aggregated information - Aggregated volume

 - Price

 N/A e) Date of the transaction December 22, 2025 f) Place of the transaction NYSE American LLC

Please see below information about transactions made under the fourth tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 29 October 2025.

The duration of the buy-back tranche: 30 October 2025 to no later than 2 February 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 29 October 2025, available here: https://newsweb.oslobors.no/message/658157

From 15 December to 19 December 2025, Equinor ASA has purchased a total of 1,624,724 own shares at an average price of NOK 232.3171 per share.

Overview of transactions:

DateTrading venueAggregated daily volume (number of shares)Daily weighted average share price (NOK)Total daily transaction value (NOK)     15 DecemberOSE321,000233.348574,904,868.50 CEUX    TQEX        16 DecemberOSE326,000229.793374,912,615.80 CEUX    TQEX        17 DecemberOSE319,724232.671174,390,534.78 CEUX    TQEX        18 DecemberOSE323,000233.172975,314,846.70 CEUX    TQEX        19 DecemberOSE335,000232.622077,928,370.00 CEUX    TQEX        Total for the periodOSE1,624,724232.3171377,451,235.78 CEUX    TQEX        Previously disclosed buy-backs under the trancheOSE9,356,067238.14372,228,088,156.85CEUX   TQEX   Total9,356,067238.14372,228,088,156.85     Total buy-backs under the tranche (accumulated)OSE10,980,791237.28162,605,539,392.62CEUX   TQEX   Total10,980,791237.28162,605,539,392.62 Following completion of the above transactions, Equinor ASA owns a total of 55,338,984 own shares, corresponding to 2.16% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 44,303,101 own shares, corresponding to 1.73% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Detailed overview of transactions

December 23, 2025 02:01 ET

 | Source:

Diversified Energy PLC

DIVERSIFIED ENERGY COMPANY

("Diversified", or the "Company")

DIVERSIFIED ENERGY COMPANY (NYSE:DEC; LSE:DEC) announces that, in accordance with the terms of its share buyback program announced on March 20, 2025, the Company has purchased 103,367 shares of common stock, par value $0.01 per share of the Company (the "Shares") in the market at a volume-weighted average price of $13.9938 per Share through Mizuho Securities USA LLC (MSUSA). The Shares acquired will, in due course, be cancelled.

Aggregated Information

Date of Purchase:December 22, 2025Aggregate Number of Shares Purchased:103,367Lowest Price Paid per Share (USD):13.93Highest Price Paid per Share (USD):14.00Volume-Weighted Average Price Paid per Share (USD):13.9938
Following the cancellation of Shares, Diversified will have 79,182,595 shares of common stock, in issue and no shares of common stock is held in treasury. This figure of 79,182,595 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), the table below contains detailed information of the individual trades made by Mizuho Securities USA LLC as part of the buyback program.

Schedule of Purchases

Aggregate
number
of
ordinary
shares
acquired
Daily
volume
weighted
average
price
paid
Daily
highest
price
paid per
share
Daily
lowest
price
per
share
Trading
Venue
4,592
$13.9920

$14.00

$13.95

ARCX
4,384
$13.9945

$14.00

$13.97

ASPN
3,533
$13.9950

$14.00

$13.99

BAML
5,356
$13.9985

$14.00

$13.99

BATS
2,804
$13.9888

$14.00

$13.93

BATY
1,636
$13.9900

$13.99

$13.99

BIDS
900
$13.9933

$14.00

$13.98

EDGA
9,026
$13.9966

$14.00

$13.98

EDGX
37,097
$13.9919

$14.00

$13.95

IEXG
10,531
$13.9935

$14.00

$13.97

JPMX
250
$13.9950

$14.00

$13.99

LEVL
59
$13.9980

$14.00

$13.99

MEMX
2,100
$14.0000

$14.00

$14.00

MSPL
1,083
$13.9935

$14.00

$13.98

SGMT
6,732
$13.9951

$14.00

$13.97

UBSA
1,207
$13.9774

$14.00

$13.96

XBOS
400
$13.9967

$14.00

$13.99

XCIS
3,914
$13.9909

$14.00

$13.96

XNAS
7,763
$13.9927

$14.00

$13.93

XNYS
Trading
venue
Currency   
NYSE
USD
$13.9938

103,367
 
For further information, please contact:

Diversified Energy Company+1 973 856 2757Doug [email protected] Vice President, Investor Relations & Corporate Communicationswww.div.energy
About Diversified Energy Company

Diversified is a leading publicly traded energy company focused on acquiring, operating, and optimizing cash generating energy assets. Through our differentiated strategy, we acquire existing, long-life assets and invest in them to improve environmental and operational performance until retiring those assets in a safe and environmentally secure manner. Recognized by ratings agencies and organizations for our sustainability leadership, this solutions-oriented, stewardship approach makes Diversified the Right Company at the Right Time to responsibly produce energy, deliver reliable free cash flow, and generate shareholder value.

Novo Nordisk's Frankfurt-listed shares opened nearly 10% higher in early trading on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill.

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma, a form of cancer.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo

Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized Phase 3 trial, and inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation

TARRYTOWN, N.Y. and PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of bronchial asthma in children aged 6 to 11 years with severe or refractory disease whose symptoms are inadequately controlled with existing therapy. This expands the previous approval in Japan in this indication for patients aged 12 years and older.

The approval in Japan is based on data from the overall population and those with a type 2 inflammation phenotype (defined by raised blood eosinophils and/or fractional exhaled nitric oxide) in VOYAGE, a global Phase 3 trial evaluating Dupixent in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. Additionally, data from EXCURSION, an open-label extension of VOYAGE that included a sub-study of exclusively Japanese pediatric patients supported the approval. In the VOYAGE trial, Dupixent added to standard-of-care asthma therapy significantly reduced severe exacerbations (by 54% to 65%, p<0.0001) and improved lung function (by 4.68% to 5.32%, p=0.0012, p=0.0009 and p=0.0036, respectively) in the overall population, those with type 2 inflammation, and those with raised blood eosinophils, compared to placebo. In the sub-study of Japanese pediatric patients, Dupixent improved lung function from baseline at 12 weeks and resulted in a low rate of severe asthma exacerbations over one year. The treatment-related adverse events most commonly reported with Dupixent were injection site reactions (erythema, edema and induration) in VOYAGE and fever, oral herpes, eosinophilia and injection site reactions (erythema and induration) in EXCURSION.

Asthma is one of the most common chronic diseases in children. Despite treatment with current standard-of-care inhaled corticosteroids and bronchodilators, children may continue to experience serious symptoms, such as coughing, wheezing and difficulty breathing. Additionally, impaired lung function in young children can have potentially long-lasting impacts, such as reduced lung growth and persistent airway obstruction, if not addressed early. Patients also may require the use of multiple courses of systemic corticosteroids that carry significant risks. Uncontrolled asthma can interfere with day-to-day activities, like sleeping, attending school and playing sports.

In addition to asthma, Dupixent is approved in Japan in certain patients with atopic dermatitis, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD). Dupixent has been approved in 50 countries around the world for the treatment of asthma in children aged 6 to 11 years.

About Dupixent
Dupixent is available in Japan as a 200 mg or 300 mg pre-filled syringe or pre-filled pen and is now available for children aged 6 to 11 years with asthma. Dupixent is intended for injection under the skin (subcutaneous injection) and is given every two or four weeks based on weight. It can be given in a clinic or at home by self-administration after training by a healthcare professional. In children younger than 12 years of age, Dupixent should be administered by a caregiver if given at home.

Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis (EoE), prurigo nodularis, CSU, COPD and bullous pemphigoid (BP) in different age populations. More than 1,300,000 patients are being treated with Dupixent globally.1

About Regeneron’s VelocImmune Technology 
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

Dupilumab Development Program 
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. 

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, lichen simplex chronicus and allergic fungal rhinosinusitis. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. 

U.S. INDICATIONS 
DUPIXENT is a prescription medicine used:

to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with AD under 6 months of age.with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with EoE under 1 year of age, or who weigh less than 33 pounds (15 kg).to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with COPD under 18 years of age.to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with CSU under 12 years of age, or who weigh less than 66 pounds (30 kg).to treat adults with bullous pemphigoid (BP). It is not known if DUPIXENT is safe and effective in children with BP under 18 years of age. DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine or to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

have eye problems.have a parasitic (helminth) infection.are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, or BP and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

Allergic reactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye, painful red or blue bumps under the skin, or red pus-filled spots on the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms. The most common side effects include:

Eczema: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache.Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).Prurigo Nodularis: eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, stomach problems (gastritis), joint pain (arthralgia), toothache, headache, and urinary tract infection.Chronic Spontaneous Urticaria: injection site reactions.Bullous Pemphigoid: joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full Prescribing Information including Patient Information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi 
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.  

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY 

Regeneron Forward-Looking Statements and Use of Digital Media 
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of bronchial asthma in children aged 6 to 11 years pursuant to the approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) discussed in this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, allergic fungal rhinosinusitis, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended September 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals)

Sanofi Disclaimers or Forward-Looking Statements 
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

Regeneron Contacts:
Media Relations
Sharon Chen
Tel: +1 914-847-1546
[email protected] Relations
Mark Hudson
Tel: +1 914-847-3482
[email protected]  Sanofi Contacts:
Media Relations
Sandrine Guendoul
Tel: +33 6 25 09 14 25
[email protected] Relations
Thomas Kudsk Larsen
Tel: +44 7545 513 693
[email protected]  Evan Berland
Tel: +1 215-432-0234
[email protected]éo Le Bourhis
Tel: + 33 6 75 06 43 81
[email protected]

Victor Rouault
Tel: +33 6 70 93 71 40
[email protected]

Timothy Gilbert
Tel: +1 516-521-2929
[email protected]

Léa Ubaldi
Tel: + 33 6 30 19 66 46
[email protected]

Alizé Kaisserian
Tel: +33 6 47 04 12 11
[email protected] Browne
Tel: +1 781-249-1766
[email protected]

Nathalie Pham
Tel: +33 7 85 93 30 17

[email protected] Châtelet
Tel: +33 6 80 80 89 90
[email protected]

Yun Li
Tel: +33 6 84 00 90 72
[email protected]

   ____________________
1 Data on File

Almaty, Dubai and Tokyo, December 23, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), and Rakuten Group, Inc. (TSE: 4755), announced today that Beeline Kazakhstan Holding, VEON’s digital operator in Kazakhstan, and Rakuten Symphony, a subsidiary of Rakuten Group, have signed a Memorandum of Understanding (MoU) to explore strategic collaboration on next-generation connectivity, digital services, and cloud-native network infrastructure.

The MoU establishes a framework for cooperation focused on the evolution of modern, software-driven telecom networks and scalable digital platforms. Under this framework, the parties will assess opportunities to deepen collaboration across priority technology areas, including Open RAN architectures, AI-powered network intelligence, next-generation digital platforms, cloud solutions, and global IoT and mobile workforce connectivity.

By combining Beeline Kazakhstan’s strong market position and expanding digital ecosystem with Rakuten Symphony’s experience in cloud-native networks and open, automated architectures, the collaboration aims to support the long-term modernization of connectivity infrastructure and the development of advanced digital services in Kazakhstan.

“Our networks and business models are undergoing a profound transformation driven by cloud, automation and artificial intelligence,” said Evgeniy Nastradin, CEO of Beeline Kazakhstan Holding. “This collaboration reflects our ambition to explore next-generation network architectures and digital platforms that can enhance efficiency, resilience, and customer experience. By pairing our local expertise with Rakuten Symphony’s global innovation capabilities, we seek to unlock new opportunities for Kazakhstan’s digital ecosystem.”

“We are delighted to expand our partnership with VEON through this collaboration with Beeline Kazakhstan, a forward-thinking operator that shares our vision for the future of telecommunications,” said Sharad Sriwastawa, President of Rakuten Symphony. “Today’s announcement underscores our shared commitment to driving the future of telecom with open, cloud-native architectures. By combining our expertise in Open RAN, AI-powered automation, and digital platforms with Beeline Kazakhstan's local expertise, we aim to deliver innovation and enhanced digital experiences for the region.”

“Beeline Kazakhstan has consistently demonstrated its leadership in translating advanced technologies into meaningful digital services for the people of Kazakhstan and the broader region,” said Kaan Terzioglu, VEON Group CEO. “This collaboration will enable us to explore how Rakuten Symphony’s cutting-edge capabilities and business model can enhance Beeline Kazakhstan’s continued network evolution and digital service ambitions. We are delighted to expand our collaboration with Rakuten to a second VEON Group company following Kyivstar Group in Ukraine.”

Kyivstar Group, another VEON Group Company, is already partnering with Rakuten Symphony in Ukraine to explore Open RAN collaboration.

About VEON  

VEON is a digital operator that provides connectivity and digital services to nearly 150 million connectivity and 140 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

About Beeline Kazakhstan

Beeline Kazakhstan serves 11.9 million customers with mobile connectivity and around one million with fixed internet services. Since 2018, the company has been executing its digital operator strategy. Over the past five years, leveraging its expertise in digital solution development, Beeline Kazakhstan has created an ecosystem of 60 internal and external products. Beeline Kazakhstan is majority-owned by VEON.

About Rakuten
Rakuten Group, Inc. (TSE: 4755) is a global technology leader in services that empower individuals, communities, businesses and society. Founded in Tokyo in 1997 as an online marketplace, Rakuten has expanded to offer services in e-commerce, fintech, digital content and communications to 2 billion members around the world. The Rakuten Group has around 30,000 employees, and operations in 30 countries and regions. For more information visit https://global.rakuten.com/corp/.  

About Rakuten Symphony
Rakuten Symphony is reimagining telecom, changing supply chain norms and disrupting outmoded thinking that threatens the industry’s pursuit of rapid innovation and growth. Based on proven modern infrastructure practices, its open interface platforms make it possible to launch and operate advanced services in a fraction of the time and cost of conventional approaches, with no compromise to network quality or security. Rakuten Symphony has operations in Japan, the United States, Singapore, India, South Korea, Europe and the Middle East Africa region. For more information about Rakuten Symphony’s offerings, visit: https://symphony.rakuten.com.

Forward-Looking Statements Disclaimer
This release contains “forward-looking statements”, within the meaning of the Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to VEON’s strategic ambitions and changes in technology. There are numerous risks, uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to VEON’s strategic ambitions and changes in technology, among others discussed in the section entitled “Risk Factors” in VEON’s 2024 Form 20-F filed with the SEC on April 25, 2025 and other public filings made by VEON with the SEC. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law.

Contact Information
VEON 
Hande Asik
Chief Communications and Strategy Officer
[email protected]

Beeline Kazakhstan and Rakuten Symphony signing ceremony

Beeline Kazakhstan and Rakuten Symphony signing ceremony
Beeline Kazakhstan Telecommunication Services CEO Jabbor Kayumov and Rakuten Symphony President Shar...

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

HomeStock IdeasLong IdeasIndustrial 

SummaryStanley Black & Decker is on course to witness a second calendar year of negative returns, while also underperforming its industrial and broader peers from the S&P 500.SWK is not yet flourishing, as conditions in its key end markets look mixed, particularly the residential construction markets.Yet, SWK's margin expansion is on track, with gross margins expected to reach 35% by end of next year, aided by greater pricing, cost reductions, and supply chain localization.Free cash flow is projected to cover dividends by 120% in 2025, supporting deleveraging and dividend sustainability, with further inventory improvements expected in FY26.SWK trades at a forward FCF yield of 5.3%, 11x FY27 P/E, with a PEG of 0.5x, and looks like a good mean-reversion bet within the industrials landscape. monticelllo/iStock via Getty Images

Another Disappointing Year Beckons Stanley Black & Decker (SWK) is a longstanding industrial company (a +180-year history), that is noted for its wide portfolio products of tools, outdoor products, and engineered fastener systems, that are primarily used in the construction (both residential & non-residential), automotive, aerospace, and general industrial markets.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Investors have high hopes that Tesla will monetize its robotaxi and robotics initiatives.

Tesla (TSLA +1.57%) stock has been on a tear -- hitting an all-time high on Dec. 15. Tesla is now within striking distance of surpassing Meta Platforms and Broadcom (AVGO +0.51%) in market capitalization to become the sixth-most-valuable U.S. company, behind only Nvidia (NVDA +1.51%), Apple, Alphabet (GOOG +0.88%) (GOOGL +0.85%), Microsoft, and Amazon.

Tesla is surging due to investor excitement over the company's robotics and artificial intelligence (AI) investments -- particularly its autonomous driving technology through its expanding robotaxi project. Investors are betting that Tesla's future will depend less on selling electric vehicles (EVs) to households and more on self-driving cars, Optimus robots, etc.

But to fund these efforts, Tesla relies on cash flows from its automotive and energy generation and storage segments. Tesla's profitability has taken a massive hit, as growth is slowing and its costs are rising. Its operating margins in the third quarter of 2025 were just 5.8% compared to 10.8% in the same quarter of 2024.

Tesla is being valued for what it could earn in the future rather than what it is earning today. Even if Tesla delivers exceptional results, it could still be a poorly performing stock over the next three to five years because so much optimism is already being factored into the valuation. A much better opportunity for 2026 and beyond is a company with plenty of growth potential but a much more realistic valuation -- Nvidia.

Image source: Tesla.

Nvidia's cash flows fuel its innovation
Unlike Tesla, Nvidia is already capitalizing on a massive opportunity in AI by selling graphics processing units (GPUs) and associated software and hardware to data centers -- a significant change from Nvidia's previous key end markets in gaming, professional visualization, and automotive.

Nvidia has been in the spotlight lately due to mounting competition from Advanced Micro Devices and Broadcom. Broadcom works with hyperscalers like Alphabet to develop custom AI chips. Broadcom and Alphabet have been collaborating for several years, but the relationship has entered a new gear as Alphabet uses these custom chips to train AI models. Alphabet is considering selling its custom chips, called tensor processing units, to other hyperscalers like Meta Platforms. If Alphabet can rival Nvidia with a customer-built full-stack solution that doesn't depend on its GPUs, it could erode Nvidia's margins. That threat has been reflected in the stock prices of both companies -- Nvidia is up just a couple of percentage points over the last three months, compared to a 21% gain for Alphabet.

Nvidia's margins could fall, and it could still become the most profitable company (in addition to being the most valuable) in the world in the coming years. Nvidia has an exceptional balance sheet and generates tons of free cash flow that it can use to invest in long-term projects and ramp up research and development (R&D) spending.

Nvidia's cash-supported R&D gives it a rapidly evolving product pipeline. It could have easily rested on its laurels after developing its Blackwell architecture. Instead, Nvidia plans to release its new class of GPUs, called Rubin, which are specifically engineered for AI systems. Rubin will use Taiwan Semiconductor Manufacturing's highly advanced 3-nanometer process, which packs more transistors into each microchip to increase performance.

Today's Change

(

1.51

%) $

2.73

Current Price

$

183.72

Nvidia's valuation is reasonable, while Tesla's is built on speculation
With Tesla's EV business under pressure, the company needs to begin generating positive cash flow from its other efforts to support long-term growth projects. Nvidia, on the other hand, is already a high-margin cash cow that is well-positioned to address mounting competition.

Additionally, Nvidia trades at a much more reasonable 37.2 times forward earnings. Tesla's is a mind-numbing 292.9.

Nvidia and Tesla have both delivered impeccable returns for long-term investors. But for 2026, Nvidia has a far better profile of risk to potential reward than Tesla, which has a mountain to climb just to meet investor expectations and could get punished for even minor missteps.

Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") announces it has closed the first tranche (the "First Tranche") of its non-brokered private placement (the "Private Placement") flow-through units (the " FT Units") as previously announced in the Company's news release dated December 17, 2025.

The First Tranche consisted of the issuance of 557,769 Flow Through Units at a price of $1.30 per Unit for aggregate gross proceeds of $725,099.70. Each FT Unit shall consist of one common share of the Corporation (a "FT Share") and one common share purchase warrant (each, a "Warrant") (each of which qualifies as a "flow-through share" within the meaning of subsection 66(15) the Income Tax Act (Canada) (the "ITA"). Each Warrant entitles the holder thereof to purchase one common share of the Corporation (a "Warrant Share") (on a non-"flow-through" basis) at an exercise price of $2.00 per Warrant Share for a period of 24 months following the Closing Date being December 23, 2026.

Proceeds from the First Tranche will be used to fund the current exploration program on the Company's BC projects, particularly for the polymetallic Hat Project located in northwestern BC. In connection with the closing of the first tranche the Company will pay finders fees to Research Capital Corporation the fees include $2,502.50 in Cash and 1,925 non transferable Finders warrants issued under the same terms as the Units noted above.

All securities issued pursuant to the First Tranche are subject to a four-month-and-one-day hold period expiring April 23, 2026, in accordance with applicable securities laws.

The Private Placement is subject to the final approval of the TSX Venture Exchange. The Company anticipates closing the remaining portion of the Private Placement in the coming weeks.

About Doubleview Gold Corp

A mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX-Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: A1W038) and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.

Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.

On behalf of the Board of Directors,
Farshad Shirvani, President & Chief Executive Officer

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Private Placement and other statements concerning the Private Placement; the anticipated use of proceeds from the Private Placement; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278896

Source: Doubleview Gold Corp.

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us